Sagespring Wealth Partners LLC Takes Position in Edwards Lifesciences Corporation $EW

Sagespring Wealth Partners LLC acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,327 shares of the medical research company’s stock, valued at approximately $803,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GDS Wealth Management raised its stake in shares of Edwards Lifesciences by 4.2% in the 3rd quarter. GDS Wealth Management now owns 225,998 shares of the medical research company’s stock valued at $17,576,000 after purchasing an additional 9,046 shares during the period. Financial Life Planners acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $93,000. UniSuper Management Pty Ltd lifted its stake in Edwards Lifesciences by 29.8% in the 3rd quarter. UniSuper Management Pty Ltd now owns 64,031 shares of the medical research company’s stock valued at $4,980,000 after acquiring an additional 14,695 shares in the last quarter. Jennison Associates LLC boosted its position in Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. Finally, Westfuller Advisors LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $79,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Citigroup restated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a report on Monday, January 12th. Finally, BTIG Research reissued a “buy” rating and set a $103.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Trading Up 0.7%

Edwards Lifesciences stock opened at $84.23 on Tuesday. The stock has a 50-day simple moving average of $84.98 and a 200 day simple moving average of $80.89. The stock has a market capitalization of $48.88 billion, a P/E ratio of 36.30, a PEG ratio of 3.19 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company earned $0.67 earnings per share. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 57,824 shares of company stock valued at $4,863,323 in the last quarter. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.